IMHA Treatment & Dose References
Access species-specific educational treatment and dose references for canine, feline and equine IMHA. Evidence strength differs substantially between species: canine recommendations are supported by the 2019 ACVIM treatment consensus [Swann et al., 2019], while feline and equine guidance relies more heavily on pharmacological studies, retrospective clinical evidence and case reports.
Canine Calculator
Derived principally from the 2019 ACVIM Consensus Statement on the Treatment of IMHA in Dogs [Swann et al., 2019]. Includes published glucocorticoid, adjunct immunosuppressive and thromboprophylaxis reference ranges, with treatment decisions remaining case-specific.
- ✓ Published glucocorticoid reference ranges
- ✓ Adjunct immunosuppressive considerations
- ✓ ACVIM thromboprophylaxis guidance
Feline Calculator
Based on published feline pharmacology and retrospective clinical studies, including a 2026 cohort of 37 cats with non-associative IMHA [Kulmer et al., 2026]. There is no feline equivalent of the 2019 canine ACVIM treatment consensus, so dose references and antithrombotic choices require case-specific veterinary judgement.
- ✓ Prednisolone — feline literature reference
- ✓ Mycophenolate — limited feline IMHA evidence
- ✓ Clopidogrel — feline antiplatelet reference
Equine Calculator
Based on published equine pharmacology, case reports and retrospective clinical literature, including the 25-equid study of Easton-Jones and colleagues [Easton-Jones et al., 2021]. There is no widely accepted equine-specific IMHA treatment consensus, so displayed doses are reference values rather than a standard treatment protocol.
- ✓ Dexamethasone — equine literature reference
- ✓ UFH / LMWH — antithrombotic references
- ✓ Corticosteroid adverse-effect awareness
Thrombotic disease is a major complication of canine IMHA, and the 2019 ACVIM consensus strongly recommends thromboprophylaxis in dogs with IMHA except where severe thrombocytopenia or another contraindication makes treatment inappropriate [Swann et al., 2019]. Evidence in feline and equine IMHA is substantially less complete, and antithrombotic treatment in those species should be individualised.
Anticoagulant and antiplatelet strategies are not universally interchangeable. In canine IMHA, anticoagulants may be used alone or in combination with antiplatelet drugs according to thrombotic and bleeding risk. Feline and equine treatment choices should be based on species-specific evidence, current formulary guidance and the individual patient.
Review the consensus statements and peer-reviewed studies underpinning the clinical references in this portal.